Role of IKKe in the Metabolic Diseases: Physiology, Pathophysiology, and Pharmacology

作者：Xiao, Qing-Ao; He, Qian; Li, Lun; Song, Yinhong; Chen, Yue-ran; Zeng, Jun^*; Xia, Xuan^*

来源：Frontiers in Pharmacology, 2022, 13: 888588.

DOI：10.3389/fphar.2022.888588

• inhibitor of nuclear factor kappa-B kinase epsilon
• nonalcoholic fatty liver disease
• diabetes
• obesity
• metabolic diseases
• amlexanox

IKK epsilon (inhibitor of nuclear factor kappa-B kinase epsilon) is a member of the noncanonical NF-kappa B pathway. It participates in the inflammatory response and innate immunity against bacteria. In recent decades, IKK epsilon has been closely associated with metabolic regulation. Inhibition of the IKK epsilon pathway can improve fat deposition in the liver, reduce subcutaneous fat inflammation, and improve liver gluconeogenesis in obesity. IKK epsilon is expected to be a new therapeutic target for metabolic diseases such as nonalcoholic fatty liver disease, diabetes, and obesity. Herein, we summarize the structural characterization, physiological function, and pathological role of IKK epsilon in metabolic diseases and small molecule inhibitors of IKK epsilon.

• 单位
  1